黏蛋白1与肿瘤相关蛋白的调控网络研究

doi:10.3969/j.issn.1674-8115.2022.08.007

摘要/Abstract

摘要：

目的·研究黏蛋白1（mucin1，MUC1）在不同肿瘤组织中的表达水平及其对患者生存期的影响；通过分析与MUC1存在相互作用的肿瘤相关蛋白的调控网络，预测MUC1参与肿瘤发生发展的可能机制。方法·使用GEPIA 2在线平台对MUC1在33种肿瘤中的mRNA水平，以及其与患者生存期的关系进行分析。在HEK293T细胞中转染MUC1-HA质粒，用HA抗体进行免疫共沉淀（co-immunoprecipitation，Co-IP）实验，对MUC1结合蛋白进行液相色谱-串联质谱（liquid chromatography-tandem mass spectrometry，LCMS/MS）分析。使用String 11.5在线平台对MUC1结合蛋白的亚细胞定位、分子功能、涉及的疾病、参与的生物学过程以及这些蛋白之间的相互作用调控网络进行分析。结果·MUC1在乳腺癌、宫颈癌、弥漫性大B细胞瘤、多发性胶质细胞瘤、低级别脑胶质瘤、卵巢癌、胰腺癌、胸腺癌和子宫内膜癌等9种肿瘤中高表达；对这9种肿瘤中MUC1表达与生存期的关系分析发现，MUC1表达与生存期呈负相关，其中在乳腺癌、宫颈癌、多发性胶质细胞瘤、低级别脑胶质瘤、胰腺癌和胸腺癌等6种肿瘤中具有统计学意义。质谱分析共检测到526个MUC1结合蛋白，这些蛋白定位于细胞器、细胞质和膜结构最多；主要分子功能包括蛋白结合、离子结合和酶活性等；涉及的疾病有解剖实体性疾病、细胞增殖性疾病、代谢性疾病和癌症等；参与的生物学过程主要包括细胞应激、代谢、发育和生物合成等。MUC1结合蛋白主要参与代谢、癌症、cGMP-依赖cGMP的蛋白激酶（cGMP-dependent protein kinase，PKG）、肿瘤坏死因子（tumor necrosis factor，TNF）和细胞周期等信号通路；深入分析后发现，MUC1结合蛋白一方面大量参与到Wnt/β-catenin、Notch和cAMP等癌症相关信号通路，另一方面通过调控代谢、凋亡和细胞周期促进肿瘤的发生发展。结论·MUC1在多种肿瘤组织中高表达并与患者预后不良相关；MUC1通过蛋白相互作用参与调控细胞代谢和肿瘤相关信号通路。该研究创新性地发现多个新的MUC1结合蛋白，可为进一步研究MUC1生物学新功能奠定基础。

关键词: 黏蛋白1, 肿瘤, 生存分析, 蛋白质组, 信号通路

Abstract:

Objective ·To investigate the level of the expression of mucin 1 (MUC1) in different cancers and its impact on patient survival, and predict the possible mechanisms of MUC1 involvement in oncogenesis and tumor progression by analyzing the regulatory network of tumor-associated proteins that interact with MUC1. Methods ·The mRNA levels of MUC1 in 33 tumors and the relationship between the expression of MUC1 and patient survival were analyzed by using the GEPIA 2 online platform. MUC1-HA plasmids were transfected in HEK293T cells, and then MUC1-binding proteins were obtained by co-immunoprecipitation (Co-IP) experiments with HA antibody, which was later analyzed by liquid chromatography-tandem mass spectrometry (LCMS/MS). The subcellular localization, molecular function, diseases involved, biological process of MUC1-binding proteins and the regulatory network of interactions between these proteins were analyzed by using String 11.5 online platform. Results ·MUC1 was highly expressed in 9 kinds of tumors, including breast cancer, cervical cancer, diffuse large B-cell tumor, glioblastoma multiforme, brain lower grade glioma, ovarian carcinoma, pancreatic carcinoma, thymoma, and uterine corpus carcinoma. The relationship between MUC1 expression and overall survival in these 9 kinds of tumors was analyzed, and MUC1 expression was found to be negatively correlated with the overall survival. Higher MUC1 expression was related to significantly shorter survival time in 6 kinds of tumors, including breast cancer, cervical cancer, glioblastoma multiforme, brain lower grade glioma, pancreatic carcinoma, and thymoma. A total of 526 MUC1-binding proteins were detected by mass spectrometry analysis, and these proteins were mostly localized in organelles, cytoplasm, and membrane structures. The main molecular functions of these proteins included protein binding, ion binding, and enzymatic activity. They were primarily involved in anatomical entity diseases, cell proliferation diseases, metabolic diseases, and cancers. The related biological processes largely consisted of cellular stress, metabolism, development, and biosynthesis. MUC1-binding proteins played various roles in signaling pathways of metabolism, cancer, cGMP-cGMP-dependent protein kinase (PKG), tumor necrosis factor (TNF), and cell cycle. Further analysis of MUC1-binding-protein-associated signaling pathways revealed that they were heavily implicated in cancer-related signaling pathways such as Wnt/β-catenin, Notch, and cAMP on the one hand, and promoted tumor development by regulating metabolism, apoptosis, and cell cycle on the other hand. Conclusion ·MUC1 is highly expressed in a variety of tumor issues and is associated with poor prognosis of patients. MUC1 regulates cellular metabolism and plays a part in tumor-related signaling pathways possibly through protein interactions. This study innovatively identifies several new MUC1-binding proteins, which lay the foundation for further investigation of new biological functions of MUC1.

Key words: mucin 1 (MUC1), tumor, survival analysis, proteome, signaling pathway

中图分类号:

褚云开, 廖春华, 邓华云, 黄雷. 黏蛋白1与肿瘤相关蛋白的调控网络研究[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1024-1033.

CHU Yunkai, LIAO Chunhua, DENG Huayun, HUANG Lei. Study of the regulatory network of MUC1 and tumor-associated proteins[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1024-1033.

图/表 5

图1 MUC1 在不同肿瘤组织中的转录水平Note： Red indicates high expression of MUC1. Green indicates low expression of MUC1. Black indicates no significant difference. T—tumor tissue. N—normal tissue.CHOL—cholangiocarcinoma; COAD—colon adenocarcinoma; ESCA—esophageal carcinoma; HNSC—head and neck squamous cell carcinoma; KICH—kidney chromophobe; KIRC—kidney renal clear cell carcinoma; KIRP—kidney renal papillary cell carcinoma; LAML—acute myeloid leukemia; LIHC—liver hepatocellular carcinoma; LUAD—lung adenocarcinoma; LUSC—lung squamous cell carcinoma; MESO—mesothelioma; PCPG—pheochromocytoma and paraganglioma; PRAD—prostate adenocarcinoma; READ—rectum adenocarcinoma; SARC—sarcoma; SKCM—skin cutaneous melanoma; STAD—stomach adenocarcinoma; TGCT—testicular germ cell tumors; THCA—thyroid carcinoma; UCS—uterine carcinosarcoma; UVM—uveal melanoma.

Fig 1 Transcription levels of MUC1 in different tumor tissues

图2 9种癌症中 MUC1 表达与患者OS的关系

Fig 2 Relationship between MUC1 expression and OS in 9 kinds of cancers

图3 MUC1结合蛋白的亚细胞定位和分子功能分析Note：A. Subcellular localization of MUC1-binding proteins. B. Molecular function of MUC1-binding proteins.

Fig 3 Subcellular localization and molecular function of MUC1-binding proteins

图4 与MUC1结合蛋白有关的疾病、生物学进程和信号通路Note：A. Diseases associated with MUC1-binding proteins. B. Biological processes associated with MUC1-binding proteins. C. Signaling pathways associated with MUC1-binding proteins.

Fig 4 Diseases, biological processes and signaling pathways associated with MUC1-binding proteins

图5 MUC1结合蛋白参与的信号通路Note：A. Pathways in cancer. B. Metabolic pathway. C. cGMP-PKG signaling pathway. D. TNF signaling pathway. E. Cell cycle.

Fig 5 Signaling pathways of MUC1-binding proteins

参考文献 47

1	LI W, HAN Y, SUN C, et al. Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer[J]. Theranostics, 2022, 12(3): 999-1011.
2	LAKSHMANAN I, PONNUSAMY M P, MACHA M A, et al. Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications [J]. J Thorac Oncol, 2015, 10(1): 19-27.
3	REN J, AGATA N, CHEN D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents[J]. Cancer Cell, 2004, 5(2): 163-175.
4	MORI Y, AKITA K, TANIDA S, et al. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells[J]. J Biol Chem, 2014, 289(51): 35193-35204.
5	LI Y, PANG Z, DONG X, et al. MUC1 induces M2 type macrophage influx during postpartum mammary gland involution and triggers breast cancer[J]. Oncotarget, 2017, 9(3): 3446-3458.
6	RAJABI H, AHMAD R, JIN C, et al. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells[J]. Prostate, 2012, 72(15): 1659-1668.
7	JIN W, LIAO X, LV Y, et al. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner[J]. Cell Death Dis, 2017, 8(8): e2980.
8	LV Y, CANG W, LI Q, et al. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer[J]. Oncogenesis, 2019, 8(12): 70.
9	RAINA D, KOSUGI M, AHMAD R, et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells[J]. Mol Cancer Ther, 2011, 10(5): 806-816.
10	HUANG L, REN J, CHEN D, et al. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation[J]. Cancer Biol Ther, 2003, 2(6): 702-706.
11	HUANG L, CHEN D, LIU D, et al. MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin[J]. Cancer Res, 2005, 65(22): 10413-10422.
12	LI Y, YI H, YAO Y, et al. The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin[J]. PLoS One, 2011, 6(4): e19102.
13	HUANG L, LIAO X, BECKETT M, et al. MUC1-C oncoprotein interacts directly with ATM and promotes the DNA damage response to ionizing radiation[J]. Genes Cancer, 2010, 1(3): 239-250.
14	LIAO C, YU L, PANG Z, et al. WWP1 targeting MUC1 for ubiquitin-mediated lysosomal degradation to suppress carcinogenesis[J]. Signal Transduct Target Ther, 2021, 6(1): 297.
15	SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2018, 47(D1): D607-D613.
16	ASTER J C, PEAR W S, BLACKLOW S C. The varied roles of Notch in cancer[J]. Annu Rev Pathol, 2017, 12: 245-275.
17	WANG Y, ZHAI S, XING J, et al. LncRNA GAS5 promotes abdominal aortic aneurysm formation through regulating the miR-185-5p/ADCY7 axis[J]. Anticancer Drugs, 2022, 33(3): 225-234.
18	KINKL N, HAGEMAN G S, SAHEL J A, et al. Fibroblast growth factor receptor (FGFR) and candidate signaling molecule distribution within rat and human retina[J]. Mol Vis, 2002, 8: 149-160.
19	MARTÍNEZ-REYES I, CHANDEL N S. Mitochondrial TCA cycle metabolites control physiology and disease[J]. Nat Commun, 2020, 11(1): 102.
20	ROMEO S. ACAT2 as a novel therapeutic target to treat fatty liver disease[J]. J Intern Med, 2022, 292(2): 175-176.
21	VAMECQ J, ANDREOLETTI P, EL KEBBAJ R, et al. Peroxisomal acyl-CoA oxidase type 1: anti-inflammatory and anti-aging properties with a special emphasis on studies with LPS and argan oil as a model transposable to aging[J]. Oxid Med Cell Longev, 2018, 2018: 6986984.
22	RODIONOV R N, JARZEBSKA N, WEISS N, et al. AGXT2: a promiscuous aminotransferase[J]. Trends Pharmacol Sci, 2014, 35(11): 575-582.
23	PLAITAKIS A, LATSOUDIS H, SPANAKI C. The human GLUD2 glutamate dehydrogenase and its regulation in health and disease[J]. Neurochem Int, 2011, 59(4): 495-509.
24	PIAZZA G A, WARD A, CHEN X, et al. PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity[J]. Drug Discov Today, 2020, 25(8): 1521-1527.
25	ZOU T, LIU J, SHE L, et al. A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer[J]. J Cancer, 2019, 10(27): 6848-6857.
26	GAO Z, LEI W I, LEE L T O. The role of neuropeptide-stimulated cAMP-EPACs signalling in cancer cells[J]. Molecules, 2022, 27(1): 311.
27	DONG Y, CHEN H, GAO J, et al. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease[J]. J Mol Cell Cardiol, 2019, 136: 27-41.
28	MCILWAIN D R, BERGER T, MAK T W. Caspase functions in cell death and disease[J]. Cold Spring Harb Perspect Biol, 2013, 5(4): a008656.
29	YUE J, LÓPEZ J M. Understanding MAPK signaling pathways in apoptosis[J]. Int J Mol Sci, 2020, 21(7): E2346.
30	PIWARSKI S A, THOMPSON C, CHAUDHRY A R, et al. The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells[J]. Biochem Pharmacol, 2020, 174: 113845.
31	FUJII W, NISHIMURA T, KANO K, et al. CDK7 and CCNH are components of CDK-activating kinase and are required for meiotic progression of pig oocytes[J]. Biol Reprod, 2011, 85(6): 1124-1132.
32	DEGREGORI J. The genetics of the E2F family of transcription factors: shared functions and unique roles[J]. Biochim Biophys Acta, 2002, 1602(2): 131-150.
33	REN J, BHARTI A, RAINA D, et al. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90[J]. Oncogene, 2006, 25(1): 20-31.
34	AHMAD R, ALAM M, RAJABI H, et al. The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function[J]. J Biol Chem, 2012, 287(25): 20866-20875.
35	FRUMAN D A, CHIU H, HOPKINS B D, et al. The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635.
36	CUI C, MERRITT R, FU L, et al. Targeting calcium signaling in cancer therapy[J]. Acta Pharm Sin B, 2017, 7(1): 3-17.
37	JIN C, RAJABI H, PITRODA S, et al. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells[J]. PLoS One, 2012, 7(7): e39432.
38	RAJABI H, HIRAKI M, TAGDE A, et al. MUC1-C activates EZH2 expression and function in human cancer cells[J]. Sci Rep, 2017, 7(1): 7481.
39	MA J, RUBIN B K, VOYNOW J A. Mucins, mucus, and goblet cells[J]. Chest, 2018, 154(1): 169-176.
40	PARK J A, PARK S, CHOI J K, et al. Inhibition of MUC1-C increases ROS and cell death in mouse embryonic stem cells[J]. Int J Stem Cells, 2021, 14(2): 180-190.
41	HAGIWARA M, YASUMIZU Y, YAMASHITA N, et al. MUC1-C activates the BAF (mSWI/SNF) complex in prostate cancer stem cells[J]. Cancer Res, 2021, 81(4): 1111-1122.
42	AGATA N, AHMAD R, KAWANO T, et al. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8[J]. Cancer Res, 2008, 68(15): 6136-6144.
43	CHEN Q, LI D, REN J, et al. MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress[J]. Biochem Biophys Res Commun, 2013, 440(1): 179-183.
44	SUN C C, ZHOU Q, HU W, et al. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma[J]. Aging (Albany NY), 2018, 10(5): 973-987.
45	TAN P Y, WEN L J, LI H N, et al. miR-548c-3p inhibits the proliferation, migration and invasion of human breast cancer cell by targeting E2F3[J]. Cytotechnology, 2020, 72(5): 751-761.
46	TYAGI A, AGARWAL C, AGARWAL R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention[J]. Mol Cancer Ther, 2002, 1(7): 525-532.
47	EVAN G I, VOUSDEN K H. Proliferation, cell cycle and apoptosis in cancer[J]. Nature, 2001, 411(6835): 342-348.

[1]	刘宏强, 陆艳青, 高宇轩, 王一云, 王传东, 张晓玲. 构建高效载体OPEI沉默TRAF6促进骨关节炎软骨再生的研究[J]. 上海交通大学学报（医学版）, 2022, 42(7): 846-857.
[2]	王雨心, 孙瑞琪, 刘坚华, 何伟娜. 开发用于肿瘤微环境成像的pH敏感荧光探针[J]. 上海交通大学学报（医学版）, 2022, 42(7): 875-884.
[3]	胡晓, 张鑫, 谷阳. 体质量与C1q肿瘤坏死因子相关蛋白1在心肌梗死患者中的交互作用[J]. 上海交通大学学报（医学版）, 2022, 42(6): 786-791.
[4]	郑诗凡, 马皎. 肿瘤干细胞代谢在肿瘤发展中作用的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(6): 825-832.
[5]	张修齐, 沈柏用. 胰腺导管腺癌神经侵袭的细胞学机制研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(6): 833-838.
[6]	朱田雨, 宗春燕, 许诗琼, 葛盛芳, 范先群, 贾仁兵. 结膜黑色素瘤组织病理学特征、Ki-67表达和预后的关系[J]. 上海交通大学学报（医学版）, 2022, 42(5): 617-623.
[7]	陈卫宏, 侯黎莉, 杨玲, 毛艳, 张金凤. 冷冻疗法预防头颈癌患者放射性口腔黏膜炎的meta分析[J]. 上海交通大学学报（医学版）, 2022, 42(5): 635-645.
[8]	王慧, 赵莹, 温丽蓉, 曹军, 羊继平, 原永明. 前列腺癌患者血液中PSA、TAP、MACC1的表达及其诊断价值[J]. 上海交通大学学报（医学版）, 2022, 42(4): 496-501.
[9]	许静轩, 杜少倩, 曹源, 王红霞, 黄伟翼. MMP14在胰腺癌中的表达及其与肿瘤免疫微环境特征的相关性研究[J]. 上海交通大学学报（医学版）, 2022, 42(3): 312-322.
[10]	邢正文, 吴滢, 王雪莉, 王庆煜, 王文婷, 李治, 张彬, 金晶. 8例儿童卵巢颗粒细胞瘤临床病理特征及预后分析[J]. 上海交通大学学报(医学版), 2022, 42(2): 192-196.
[11]	李彦庆, 王晓霞, 贾向东, 任猛, 许天祥. 桥粒黏蛋白2在消化系统肿瘤中的功能研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 247-252.
[12]	程培培, 杜亚松. 白细胞介素-1受体辅助蛋白在神经精神疾病发病中作用的研究进展[J]. 上海交通大学学报(医学版), 2022, 42(1): 101-106.
[13]	徐艳丽, 管文斌, 茅伟伟, 朱传营, 张勤, 袁晓军, 谈珍. 52例颅内非典型畸胎样/横纹肌样瘤的临床特征及生存分析[J]. 上海交通大学学报(医学版), 2021, 41(9): 1222-1227.
[14]	周天浩, 辛肇晨, 杜少倩, 曹源, 许静轩, 劳曾红, 王红霞. 乳腺癌类器官共培养技术的建立和优化[J]. 上海交通大学学报(医学版), 2021, 41(8): 1017-1024.
[15]	季艳杰, 罗浩, 蔡海燕, 刘欣宇, 金诗佳, 粟深月, 徐含章, 雷虎, 吴英理. CDDO-Me对三阴性乳腺癌细胞泛素特异性蛋白酶2a活性及细胞增殖的抑制作用[J]. 上海交通大学学报(医学版), 2021, 41(8): 1025-1032.